Medtronic 780G System Real World Evidence
Specifications
- Product Name: MiniMedTM 780G system
- Indication: For use by patients aged 7-80 years with Type 1 diabetes
- Real-World Evidence: Clinical outcomes in a wide T1D population
Delivers proven clinical outcomes in a wide T1D population
Scope of the analysis and methods
- Scope of the analysis
- Uploaded on CareLink™ Personal from 27 August 2020 to 02 December 2022
- 61,481 users or caregivers who provided their consent for their data to be aggregated
- From countries where local data privacy regulation permits data analysis
- Methodology:
- 3 cohorts were analyzed for the overall population and per-user self-reported age ≤15 or >15 years*
- Post-AHCL cohort
- All users with ≥10 days of SG data after initiating AHCL (N=61,481)
- Pre- and post-AHCL cohort
- All users with ≥10 days of SG data before and after initiating AHCL (N=15,395). The analyses are adjusted for baseline TIR (pre-AHCL initiation). This is the cohort used for statistical analysis
- Longitudinal cohort
- All users with ≥10 days of SG data in each of the first 12 months after initiating AHCL (N=11,617)
The MiniMed™ 780G insulin pump is indicated for use by patients aged 7-80 years with Type 1 diabetes.
Glucose Management Indicator (GMI) based on reported mean glucose values.
Calculated using JAEB https://www.jaeb.org/gmi/.
- Medtronic data on file: MiniMed ™ 780G data was uploaded voluntarily by 61,481 users in EMEA to CareLink™ Personal, from August 2020 to Dec 2022..
- Battelino T, et al. Diabetes Care 2019; 42: 1593-1603.
Achieving glycaemic targets
The MiniMed™ 780G insulin pump is indicated for use by patients aged 7-80 years with Type 1 diabetes.
Glucose Management Indicator (GMI) based on reported mean glucose values.
Calculated using JAEB https://www.jaeb.org/gmi/.
- Medtronic data on file: MiniMed ™ 780G data was uploaded voluntarily by 61,481 users in EMEA to CareLink™ Personal, from August 2020 to Dec 2022..
- Battelino T, et al. Diabetes Care 2019; 42: 1593-1603.
Users improved clinical outcomes vs Pre-SmartGuard™ initiation
The MiniMed™ 780G insulin pump is indicated for use by patients aged 7-80 years with Type 1 diabetes.
Glucose Management Indicator (GMI) based on reported mean glucose values.
Calculated using JAEB https://www.jaeb.org/gmi/.
Medtronic data on file: MiniMed ™ 780G data was uploaded voluntarily by 61,481 users in EMEA to CareLink™ Personal, from August 2020 to Dec 2022.
Between paediatrics and adults
The MiniMed™ 780G insulin pump is indicated for use by patients aged 7-80 years with Type 1 diabetes. ** Glucose Management Indicator (GMI) based on reported mean glucose values.
Calculated using JAEB https://www.jaeb.org/gmi/.
Some users were not included in the analysis because of age not shared.
- Medtronic data on file: MiniMed ™ 780G data was uploaded voluntarily by 61,481 users in EMEA to CareLink™ Personal, from August 2020 to dec 2022..
Advanced automation features
MiniMed™ 780G system real-world outcomes
Medtronic data on file: MiniMed ™ 780G data was uploaded voluntarily by 61,481 users in EMEA to CareLink™ Personal, from August 2020 to Dec 2022..
P value nor significant
In the real-world evidence
Medtronic data on file: MiniMed ™ 780G data was uploaded voluntarily by 61,481 users in EMEA to CareLink™ Personal, from August 2020 to Dec 2022.
Users with recommended optimal settings are the ones using the combination of glucose target setting at 100 mg/dL and Active Insulin Time (AIT) at 2 hours for at least 95% of the time.
FAQ
Q: What is the age range for using the MiniMedTM 780G system?
A: The system is indicated for use by patients aged 7-80 years with Type 1 diabetes.
Q: How many users were included in the analysis for clinical outcomes?
A: The analysis included a total of 61,481 users in the Post-AHCL cohort.
Documents / Resources
 |
Medtronic 780G System Real World Evidence [pdf] User Manual 780G System Real World Evidence, 780G, System Real World Evidence, Real World Evidence, World Evidence, Evidence |
Glucose Management Indicator (GMI) | JCHR 